McKesson nets 44 deals for molecular, genetic tests

Forty-four managed care organizations have licensed McKesson's molecular and genetic diagnostic management technologies, including recent new health plan customers Molina Healthcare, Paramount Healthcare and Providence Health Plans, part of the five-state Providence Health & Services.

San Francisco-based McKesson said its molecular and genetic testing management offerings include InterQual Molecular Diagnostic Criteria, Clear Coverage, Clear Orders and analytics services. This combination provides evidence-based clinical decision support for more than 500 molecular and genetic tests.

The Clear Coverage and Clear Orders tools automate notifications and authorizations while giving providers access to medical, network and benefit policies, as well as validating coverage prior to testing and forward orders to appropriate labs. InterQual Criteria clinical decision support content is included in Clear Coverage to provide medical necessity guidelines based on evidence-based medicine.

 

 

 

 

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup